Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Optimax Holdings Berhad (0222.KL)
Kuala Lumpur, MY
Optimax Holdings Berhad functions as an investment holding enterprise primarily dedicated to providing expert eye care services and related products across Malaysia. The firm's specialized clinics offer a comprehensive suite of treatments for various ocular conditions, including cataracts, glaucoma, dry eye syndrome, conjunctivitis, age-related macular degeneration, diabetic retinopathy, retinal detachment, pterygium, keratoconus, and ptosis, among other vision-related ailments. Beyond disease management, Optimax also performs refractive surgical procedures, comprehensive eye examinations, oculoplastic surgery, and provides consultation and dispensary services. In addition to its core medical offerings, the company is also involved in marketing food products. Its reach extends beyond national borders, serving an international clientele from countries such as Indonesia, the Philippines, Singapore, Thailand, Australia, China, Hong Kong, and Japan. Optimax Holdings Berhad was established in 1995 and its corporate headquarters are located in Kuala Lumpur, Malaysia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.67% | -2.78% | -3.67% | -11.02% | -13.93% | -8.70% | -0.94% | -28.08% | -31.82% | +53.28% | +53.28% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+6.3% Q1'26: +1.0% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+6.0% Q1'26: -17.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+17.8% ★ Q1'26: +4.0% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+17.0% ★ Q1'26: +15.5% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+14.2% ★ Q1'26: +14.8% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%-0.4% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×1.56× ★ Q1'26: 1.79× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 4 Rev. Ana. 5 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
114.12M
est: 113.77M (+0.3%)
|
127.69M
est: 127.70M (0.0%)
|
135.73M
est: 140.84M (-3.6%)
|
152.72M
134.19M – 175.88M
+8.4% YoY
|
167.90M
152.20M – 174.37M
+9.9% YoY
|
186.56M
166.58M – 204.09M
+11.1% YoY
|
| EBITDA |
28.59M
est: 32.58M (-12.3%)
|
37.16M
est: 36.50M (+1.8%)
|
39.53M
est: 40.26M (-1.8%)
|
43.66M
38.36M – 50.28M
+8.4% YoY
|
48.00M
43.51M – 49.84M
+9.9% YoY
|
53.33M
47.62M – 58.34M
+11.1% YoY
|
| EBIT |
21.24M
est: 22.85M (-7.0%)
|
22.58M
est: 25.10M (-10.1%)
|
23.03M
est: 27.68M (-16.8%)
|
30.02M
26.38M – 34.57M
+8.4% YoY
|
33.00M
29.92M – 34.27M
+9.9% YoY
|
36.67M
32.74M – 40.11M
+11.1% YoY
|
| Net Income |
12.89M
est: 12.20M (+5.7%)
|
13.02M
est: 14.22M (-8.4%)
|
13.75M
est: 14.58M (-5.7%)
|
17.02M
15.02M – 17.80M
+16.8% YoY
|
19.42M
17.85M – 20.08M
+14.1% YoY
|
23.19M
19.96M – 26.02M
+19.4% YoY
|
| SGA |
—
|
—
est: 2.77M (-100.0%)
|
14.74M
est: 3.06M (+381.9%)
|
3.32M
2.92M – 3.82M
+8.4% YoY
|
3.65M
3.31M – 3.79M
+9.9% YoY
|
4.05M
3.62M – 4.43M
+11.1% YoY
|
| EPS |
0.02
est: 0.02 (+8.6%)
|
0.02
est: 0.03 (-6.8%)
|
0.03
est: 0.03 (-4.2%)
|
0.03
0.03 – 0.03
+16.8% YoY
|
0.04
0.03 – 0.04
+14.1% YoY
|
0.04
0.04 – 0.05
+19.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Boon Hock Tan | Executive Deputy Chairman | 69.6K | — |
| Sing Yee Tan | Chief Executive Officer & Non-Independent Executive Director | 69.6K | female |
| Chian Yen Ang | Chief Operating Officer | — | female |
| Say Tsui Kong | Company Secretary | — | female |
| Shi Mei Yeng | Company Secretary | — | female |
| Woei Yaw Pang | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0222.KL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
